



CMD 25-H100-Q.A

Date: 2025-04-22

**Commission Request for
Information Regarding a Hearing in
Writing (CMD-Q)**

**Demande d'information de la Commission
– Audience par écrit (CMD-Q)**

In the matter of

À l'égard de

Ontario Power Generation

Application to amend the Darlington
Nuclear Generating Station power reactor
operating licence to allow production of
additional medical isotopes

Public Hearing in Writing

Spring 2025

Ontario Power Generation

Demande visant à modifier le permis
d'exploitation d'un réacteur de puissance pour la
centrale nucléaire de Darlington en vue d'obtenir
l'autorisation de produire des isotopes médicaux
supplémentaires

Audience publique par écrit

Printemps 2025



INTRODUCTION

The Commission, in conducting a public Hearing in Writing^{1,2} to consider an application from Ontario Power Generation (OPG) to amend the Darlington Nuclear Generating Station Power Reactor Operating Licence (PROL 13.04/2025) to authorize the production of additional isotopes using the Target Delivery System (TDS), has reviewed the written submissions provided by OPG in its [application](#) and [application update](#), and by CNSC staff in Commission Member Document (CMD) [CMD 25-H100](#). The Commission has also reviewed written submissions from 7 intervenors.

On March 31, 2025, the Commission sent questions to CNSC staff and OPG through [CMD 24-H100-Q](#). CNSC staff and OPG provided responses to the Commission's questions in [CMD 25-H100.B](#) and [CMD 25-H100.1B](#), respectively. The Commission has reviewed the information provided by OPG and CNSC staff.

The Commission requires additional information with respect to the question set out below.

QUESTION

Table 1: CMD 24-H100-Q.A Question for OPG

#	Question for OPG
1.	<p>In Attachment 3 of OPG's application, OPG states that:</p> <p><i>"OPEX [operating experience] review will be conducted during the preliminary engineering phase to identify previous applicable experience and lessons learned... The results of the OPEX reviews will be documented and incorporated into this project."</i></p> <p>Provide the OPEX/lessons learned from OPG's operation of its Target Delivery System to produce Molybdenum-99 (Mo-99) and explain how these lessons have been/will be incorporated into the production of Lu-177 and Y-90.</p>

¹ [Notice of Hearing in Writing and Participant Funding](#), 2025-H-100, September 9, 2024.

² [Revised Notice of Hearing in Writing](#), 2025-H-100 Revision 1, February 14, 2025.



REQUEST

OPG's response is to be made by way of a supplemental CMD **on or before 2025-04-29**. OPG should inform the Registry of any concerns about this deadline within five working days of receiving this CMD-Q.

X

Deputy Registrar